Post by Silence Therapeutics plc

Polycythemia vera (PV) remains a chronic blood cancer with significant unmet need, including the ongoing burden of symptom management and frequent phlebotomies for people living with the disease. At Silence, we are investigating whether siRNA technology can help address these challenges through a targeted approach designed to support the body's natural iron regulation. To learn more about the condition, visit our PV eBook: https://bit.ly/4wLzvBY